Suchen
Sophia Genetics SA
SOPHZur Watchlist hinzufügen
7.860USD
-0.010-0.13%
Handelsschluss 09-11 16:00（ET）
669.10MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Sophia Genetics SA Unternehmen
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
Sophia Genetics SA Profil
BörsenkürzelSOPH
Name des UnternehmensSOPHiA GENETICS SA
IPO-datumJul 23, 2021
CEOCamblong (Jurgi)
Anzahl der mitarbeiter423
WertpapierartOrdinary Share
GeschäftsjahresendeJul 23
AddresseLa Piece 12
StadtROLLE
BörseNASDAQ OMX - NASDAQ BASIC
LandSwitzerland
PostleitzahlCH-1180
Telefon41216941060
Websitehttps://www.sophiagenetics.com/
BörsenkürzelSOPH
IPO-datumJul 23, 2021
CEOCamblong (Jurgi)
Führungskräfte von Sophia Genetics SA
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
2.82M
-1.72%
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
2.82M
-1.72%
Mr. Ross J. Muken
Mr. Ross J. Muken
Chief Executive Officer, Director
Chief Executive Officer, Director
615.78K
-1.60%
Mr. Ross J. Muken
Mr. Ross J. Muken
Chief Executive Officer, Director
Chief Executive Officer, Director
615.78K
-1.60%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
489.08K
+4.03%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
489.08K
+4.03%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
443.79K
-12.17%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
443.79K
-12.17%
Mr. Troy M. Cox
Mr. Troy M. Cox
Independent Director
Independent Director
294.96K
+6.69%
Mr. Troy M. Cox
Mr. Troy M. Cox
Independent Director
Independent Director
294.96K
+6.69%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
2.82M
-1.72%
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
2.82M
-1.72%
Mr. Ross J. Muken
Mr. Ross J. Muken
Chief Executive Officer, Director
Chief Executive Officer, Director
615.78K
-1.60%
Mr. Ross J. Muken
Mr. Ross J. Muken
Chief Executive Officer, Director
Chief Executive Officer, Director
615.78K
-1.60%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
489.08K
+4.03%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
489.08K
+4.03%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Sophia Genetics SA?
Die fünf größten Anteilseigner von Sophia Genetics SA sind: Dr. Jurgi Camblong, Ph.D.
Wie viele Institutionen halten Anteile an Sophia Genetics SA (SOPH)?
Mit Stand vom 2026Q1 halten 89 Institutionen Anteile an Sophia Genetics SA, mit einem Gesamtmarktwert von etwa 27.73M, was 38.63% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -11894064.00 gestiegen.